A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy

Table 1

The effect of fenofibrate on hemodynamic data in rats with abdominal artery constriction.

	Sham	AAC	AAC+Feno (L)	AAC+Feno (H)
AoSP (mmHg)	124.3±8.6	180.6±13.7^#	178.6±14.1	176.1±10.4
LVSP (mmHg)	134.3± 9.8	184.4±11.4^#	180.8±10.9	178.5±10.7
HR (bpm)	348.8±18.2	358.6±16.1	354.0±15.2	350.8±12.8
+dp/ (mmHg/sec.)	4.98±0.28	3.37±0.61^#	4.53±0.4	4.79±0.2
-dp/ (mmHg/sec.)	4.84±0.35	3.08±0.37^#	4.27±0.4	4.56±0.2

AoSP, aortic systolic pressure; LVSP, left ventricular systolic pressure; HR, heart rate; dp/, maximal rate of left ventricular pressure increase; dp/, maximal rate of left ventricular pressure decrease. n=6 for each group, values are mean ± SD. ^#p<0.05 versus sham group, p<0.05 versus AAC group. Feno represents fenofibrate, n=6 for each group.